The Latest

Press Releases    |    Syncromune in the News    |    Events

Press Releases

Syncromune® Inc. Presents Positive Results from SYNC-T SV-102 Phase 1 Trial at AACR Annual Meeting 2024

Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024 Initial clinical data demonstrate a very high 85% overall response rate in patients with metastatic castrate-resistant prostate cancer. FORT LAUDERDALE,…

Syncromune® Inc. to Present Initial Clinical Data from SYNC-T SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024

Syncromune® Inc. to Present Initial Clinical Data from SYNC-T™ SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024 Presentation will take place during the “Cancer Vaccines: Ready for…

About Syncromune

Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to developing SYNC-T, a completely in situ immunotherapy platform optimized for solid tumor cancers that combines partial oncolysis and a multi-target biologic drug infusion. The platform is designed to achieve personalized T cell activation, empowering the immune system to recognize and attack cancer throughout the body.  The first 2 candidates, SV-101 and SV-102 are currently in Phase 1 trials.

Syncromune in the News

AACR Cancer Research Catalyst      |     May 16, 2024

From the Bench, AACR Annual Meeting 2024: CAR Tregs, Bacteria-virus Duos, and More

OncologyTube      |     April 18, 2024

Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD

Ryan Cross     |     ENDPOINTS NEWS      |     April 10, 2024

Early cancer vaccine data breathe new life into the field, but many questions remain: #AACR24

The ASCO Post      |     April 9, 2024

Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer

Greg Slabodkin, Heather McKenzie and Tyler Patchen    |     BioSpace     |     April 9, 2024

AACR 2024: What Cancer Researchers Are Talking About

Jade Parker     |     Oncology Central     |     April 9, 2024

AACR Annual Meeting 2024: news roundup

Anette Breindl    |     BioWorld     |     April 8, 2024

AACR 24: Freezing, of all things, is one way to heat cold tumors

George Prendergast, Ph.D.   |     VJOncology     |     April 8, 2024

AACR 2024  |  Preclinical modeling of cryo-immune vaccination in solid tumors

AACR 2024  |  SYNC-T combination immunotherapy in mCRPC

AACR 2024  |  The advantages of cryo-immune vaccinations in treating metastatic cancers

BiotechTV     |     April 8, 2024

Syncromune’s AACR late-breaker of phase 1 data for the SYNC-T immunotherapy drug-device combo in mCRPC

American Association for Cancer Research (AACR)     |     April 7, 2024

A Biologic Drug-Device Combination Immunotherapy Shows Promise for Patients with Metastatic Prostate Cancer

Upcoming Events

The following are meetings and conferences that the Syncromune team plans to attend.  If you would like to meet with one of our team members, please email us at info@syncromune.com

Days

May 31 – June 4, 2024

McCormack Place
Chicago, IL

ASCO 2024 ANNUAL MEETING

BOOTH #10047

Days

June 3 – 6, 2024

San Diego Convention Center
San Diego, CA

BIO INTERNATIONAL

Days

September 13 – 17, 2024

Fira Barcelona Gran Via

Barcelona, Spain

EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2024

Meeting Information: ESMO Congress 2024

Days

November 6 – 10, 2024

G.R. Brown Convention Center

Houston, TX

SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2024

Meeting Information: Home – SITC 2024 (sitcancer.org)

Past Events

February 26 – 28, 2024

BIO CEO & INVESTOR CONFERENCE

January 8 – 11, 2024

JP MORGAN 2024 42ND ANNUAL HEALTHCARE CONFERENCE

November 3 – 5, 2023

SOCIETY FOR IMMUNOTHERAPY OF CANCERS (SITC) ANNUAL MEETING

2919 E. Commercial Blvd.
Fort Lauderdale, FL 33308